BR9910095A - Compostos inibidores de spla2 para tratamento de doença - Google Patents

Compostos inibidores de spla2 para tratamento de doença

Info

Publication number
BR9910095A
BR9910095A BR9910095-9A BR9910095A BR9910095A BR 9910095 A BR9910095 A BR 9910095A BR 9910095 A BR9910095 A BR 9910095A BR 9910095 A BR9910095 A BR 9910095A
Authority
BR
Brazil
Prior art keywords
disease treatment
inhibitor compounds
spla2 inhibitor
spla
inhibitor
Prior art date
Application number
BR9910095-9A
Other languages
English (en)
Inventor
William Louis Macias
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9910095A publication Critical patent/BR9910095A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS INIBIDORES DE sPLA~ 2~ PARA TRATAMENTO DE DOENçA''<D>. é revelado um processo para tratamento de doença inflamatória do intestino, por administração a um ser humano que necessite, de uma quantidade terapeuticamente eficaz de um inibidor de sPLA~ 2~,tal como, inibidor de sPLA~ 2~ de 1H-indol-3-glioxilamida.
BR9910095-9A 1998-05-01 1999-04-20 Compostos inibidores de spla2 para tratamento de doença BR9910095A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8387498P 1998-05-01 1998-05-01
PCT/US1999/008654 WO1999057100A1 (en) 1998-05-01 1999-04-20 Spla2 inhibitor compounds for treatment of disease

Publications (1)

Publication Number Publication Date
BR9910095A true BR9910095A (pt) 2000-12-26

Family

ID=22181224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910095-9A BR9910095A (pt) 1998-05-01 1999-04-20 Compostos inibidores de spla2 para tratamento de doença

Country Status (20)

Country Link
US (1) US6340699B1 (pt)
EP (1) EP1084108A4 (pt)
JP (1) JP2002513783A (pt)
KR (1) KR20010043190A (pt)
CN (1) CN1299348A (pt)
AU (1) AU3656299A (pt)
BR (1) BR9910095A (pt)
CA (1) CA2330856A1 (pt)
CZ (1) CZ20004052A3 (pt)
EA (1) EA200001140A1 (pt)
HR (1) HRP20000739A2 (pt)
HU (1) HUP0102243A2 (pt)
ID (1) ID27153A (pt)
IL (1) IL139019A0 (pt)
NO (1) NO20005479L (pt)
PL (1) PL343708A1 (pt)
SK (1) SK16342000A3 (pt)
TR (1) TR200003194T2 (pt)
WO (1) WO1999057100A1 (pt)
ZA (1) ZA200005563B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 X型sPLA2阻害作用を有する化合物
AU2002224531B2 (en) * 2000-07-24 2005-08-25 Dow Global Technologies Inc. Thermoplastic superabsorbent polymer blend compositions and their preparation
US20090318492A1 (en) * 2005-11-03 2009-12-24 Han-Ting Chang Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
KR20100135248A (ko) * 2008-04-01 2010-12-24 아스텔라스세이야쿠 가부시키가이샤 인돌리논 화합물
CN104042617A (zh) 2009-04-29 2014-09-17 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
US9290752B2 (en) 2013-03-13 2016-03-22 Sunny Delight Beverages Co. Process for enhancing the amylase inhibitory efficacy from phaseolus vulgaris extracts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356919A (en) 1991-05-30 1994-10-18 G. D. Searle & Co. Leukotriene B4 synthesis inhibitors
DE4218096A1 (de) 1992-06-02 1993-12-09 Boehringer Mannheim Gmbh Spiro-oxetane, Verfahren zu ihrer Herstellung und Arzneimittel
DE4323409A1 (de) 1993-07-13 1995-01-19 Boehringer Mannheim Gmbh Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
EP2341045A1 (en) 1994-04-01 2011-07-06 Eli Lilly and Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor
WO1995033462A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
AU734096B2 (en) 1996-10-30 2001-06-07 Eli Lilly And Company Substituted tricyclics
NZ506329A (en) * 1998-02-25 2004-01-30 Inst Genetics Llc Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
HRP20000739A2 (en) 2001-10-31
EA200001140A1 (ru) 2001-04-23
US6340699B1 (en) 2002-01-22
NO20005479D0 (no) 2000-10-31
CZ20004052A3 (cs) 2002-05-15
TR200003194T2 (tr) 2001-03-21
IL139019A0 (en) 2001-11-25
CA2330856A1 (en) 1999-11-11
SK16342000A3 (sk) 2002-04-04
KR20010043190A (ko) 2001-05-25
EP1084108A1 (en) 2001-03-21
EP1084108A4 (en) 2005-01-12
HUP0102243A2 (hu) 2001-10-28
PL343708A1 (en) 2001-08-27
AU3656299A (en) 1999-11-23
WO1999057100A1 (en) 1999-11-11
CN1299348A (zh) 2001-06-13
ID27153A (id) 2001-03-08
NO20005479L (no) 2000-12-20
ZA200005563B (en) 2002-01-10
JP2002513783A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson&#39;s disease
ES2191069T3 (es) Diaril-2-(5h)-furanonas como inhibidores de cox-2.
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
PT1309589E (pt) Compostos de ureia e metodos de utilizacao
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
ES2168471T3 (es) 2-(5h)-furanonas diaril-5-oxigenadas como inhibidores de la cox-2.
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER&#39;S DISEASE
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
SI1456380T1 (sl) Smad inhibitorji za zdravljenje cns bolezni
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
ATE357453T1 (de) Comt-inhibitoren
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BR9910095A (pt) Compostos inibidores de spla2 para tratamento de doença
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
PT1206444E (pt) Compostos que inibem a actividade da triptase
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
HRP20041150A2 (en) Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]